# HIBCH

## Overview
The HIBCH gene encodes the enzyme 3-hydroxyisobutyryl-CoA hydrolase, which is a crucial component of the valine catabolic pathway. This enzyme is classified as a hydrolase and is responsible for catalyzing the conversion of 3-hydroxyisobutyryl-CoA to 3-hydroxyisobutyric acid within the mitochondrial matrix. This reaction is essential for preventing the accumulation of toxic intermediates that can disrupt mitochondrial function. The HIBCH gene is nuclear-encoded, and its expression is particularly significant in metabolically active tissues such as the liver, heart, and kidney. Mutations in the HIBCH gene can lead to HIBCH deficiency, a rare metabolic disorder characterized by neurodegeneration and other severe clinical manifestations (Loupatty2007Mutations; Ferdinandusse2013HIBCH).

## Structure
The HIBCH protein, encoded by the HIBCH gene, is involved in the catabolism of valine. Its molecular structure includes specific catalytic residues, notably E169 and D177, which are essential for its enzymatic activity. The C163 residue is located near E169, and mutations at this site, such as the C163F variant, can disrupt enzyme function by introducing a bulk side chain close to E169, likely affecting the enzyme's activity. The enzyme's structure includes alpha helices and beta sheets, with the C163F variant located in a linker region between two beta sheets within the crotonase domain (D’Gama2020A).

The HIBCH protein is composed of 386 amino acid residues with a calculated molecular weight of 43 kDa (Loupatty2007Mutations). The enzyme is nuclear-encoded and functions within the mitochondria, catalyzing the conversion of 3-hydroxyisobutyryl-CoA to free 3-hydroxyisobutyric acid, a critical step in the breakdown of valine (D’Gama2020A). The enzyme's activity can be measured spectrophotometrically using its physiological substrate, S-3-hydroxyisobutyryl-CoA, and is significantly reduced in cases of HIBCH deficiency (D’Gama2020A). Specific details on the quaternary structure, post-translational modifications, or splice variant isoforms are not provided in the available context.

## Function
The HIBCH gene encodes the enzyme 3-hydroxyisobutyryl-CoA hydrolase, which plays a critical role in the catabolism of the essential amino acid valine. This enzyme catalyzes the conversion of 3-hydroxyisobutyryl-CoA to 3-hydroxyisobutyrate, a key step in the valine degradation pathway (Ferdinandusse2013HIBCH; Loupatty2007Mutations). The enzyme is active in the mitochondrial matrix, where it contributes to cellular energy metabolism by preventing the accumulation of toxic intermediates such as methacrylyl-CoA, which can inactivate mitochondrial enzymes by reacting with essential cysteine residues (Ferdinandusse2013HIBCH; Shimomura1994Purification).

In healthy human cells, 3-hydroxyisobutyryl-CoA hydrolase helps maintain the activity of mitochondrial enzymes, including those containing iron-sulfur clusters, by ensuring the availability of cysteine, which is crucial for their function (Ferdinandusse2013HIBCH). The enzyme's activity is particularly high in tissues such as the liver, heart, and kidney, reflecting its importance in these metabolically active organs (Hawes1996Primary). By facilitating the proper degradation of valine, the enzyme supports normal metabolic processes and energy production, thereby contributing to overall cellular and organismal homeostasis (Loupatty2007Mutations).

## Clinical Significance
Mutations in the HIBCH gene, which encodes the enzyme 3-hydroxyisobutyryl-CoA hydrolase, lead to a rare metabolic disorder known as HIBCH deficiency. This condition is characterized by progressive infantile neurodegeneration, developmental delay, hypotonia, and neurological regression. Patients often exhibit symptoms such as poor feeding, spastic quadriplegia, and MRI abnormalities in the basal ganglia, which can resemble Leigh syndrome (Ferdinandusse2013HIBCH; Loupatty2007Mutations; Stiles2015Successful).

HIBCH deficiency results from the impaired conversion of 3-hydroxyisobutyryl-CoA to 3-hydroxyisobutyric acid, a critical step in valine catabolism. This enzymatic block leads to the accumulation of toxic metabolites like methacrylyl-CoA, which may cause neurotoxicity and mitochondrial dysfunction (Candelo2019Syndromic; Kılıç20203HydroxyisobutyrylCoA). The disorder is associated with elevated levels of hydroxy-C4-carnitine in blood, which can aid in diagnosis (Loupatty2007Mutations).

Genetic analysis has identified various mutations in the HIBCH gene, including missense and splicing mutations, which are considered causal due to their predicted deleterious effects and absence in control alleles (Loupatty2007Mutations; Ferdinandusse2013HIBCH). The condition is autosomal recessive and may be more prevalent than previously recognized, with potential underdiagnosis in clinical settings (Stiles2015Successful; Kılıç20203HydroxyisobutyrylCoA).


## References


[1. (D’Gama2020A) Alissa M. D’Gama, William J. Brucker, Tian Zhang, Cynthia S. Gubbels, Sacha Ferdinandusse, Jiahai Shi, Patricia Ellen Grant, Grace VanNoy, Casie A. Genetti, Jane Juusola, Timothy W. Yu, Amy Kritzer, and Pankaj B. Agrawal. A phenotypically severe, biochemically “silent” case of hibch deficiency in a newborn diagnosed by rapid whole exome sequencing and enzymatic testing. American Journal of Medical Genetics Part A, 182(4):780–784, February 2020. URL: http://dx.doi.org/10.1002/ajmg.a.61498, doi:10.1002/ajmg.a.61498. This article has 5 citations.](https://doi.org/10.1002/ajmg.a.61498)

[2. (Ferdinandusse2013HIBCH) Sacha Ferdinandusse, Hans R Waterham, Simon JR Heales, Garry K Brown, Iain P Hargreaves, Jan-Willem Taanman, Roxana Gunny, Lara Abulhoul, Ronald JA Wanders, Peter T Clayton, James V Leonard, and Shamima Rahman. Hibch mutations can cause leigh-like disease with combined deficiency of multiple mitochondrial respiratory chain enzymes and pyruvate dehydrogenase. Orphanet Journal of Rare Diseases, December 2013. URL: http://dx.doi.org/10.1186/1750-1172-8-188, doi:10.1186/1750-1172-8-188. This article has 70 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1750-1172-8-188)

[3. (Stiles2015Successful) Ashlee R. Stiles, Sacha Ferdinandusse, Arnaud Besse, Vivek Appadurai, Karen B. Leydiker, E.J. Cambray-Forker, Penelope E. Bonnen, and Jose E. Abdenur. Successful diagnosis of hibch deficiency from exome sequencing and positive retrospective analysis of newborn screening cards in two siblings presenting with leigh’s disease. Molecular Genetics and Metabolism, 115(4):161–167, August 2015. URL: http://dx.doi.org/10.1016/j.ymgme.2015.05.008, doi:10.1016/j.ymgme.2015.05.008. This article has 30 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.ymgme.2015.05.008)

[4. (Kılıç20203HydroxyisobutyrylCoA) Mustafa Kılıç and Fatma Kurt-Çolak. 3-hydroxyisobutyryl-coa hydrolase deficiency in a turkish child with a novel hibch gene mutation and literature review. Molecular Syndromology, 11(3):170–175, 2020. URL: http://dx.doi.org/10.1159/000508728, doi:10.1159/000508728. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1159/000508728)

[5. (Shimomura1994Purification) Y. Shimomura, T. Murakami, N. Fujitsuka, N. Nakai, Y. Sato, S. Sugiyama, N. Shimomura, J. Irwin, J.W. Hawes, and R.A. Harris. Purification and partial characterization of 3-hydroxyisobutyryl-coenzyme a hydrolase of rat liver. Journal of Biological Chemistry, 269(19):14248–14253, May 1994. URL: http://dx.doi.org/10.1016/s0021-9258(17)36781-9, doi:10.1016/s0021-9258(17)36781-9. This article has 52 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0021-9258(17)36781-9)

[6. (Hawes1996Primary) John W. Hawes, Jerzy Jaskiewicz, Yoshiharu Shimomura, Boli Huang, Jamie Bunting, Edwin T. Harper, and Robert A. Harris. Primary structure and tissue-specific expression of human β-hydroxyisobutyryl-coenzyme a hydrolase. Journal of Biological Chemistry, 271(42):26430–26434, October 1996. URL: http://dx.doi.org/10.1074/JBC.271.42.26430, doi:10.1074/jbc.271.42.26430. This article has 75 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/JBC.271.42.26430)

[7. (Candelo2019Syndromic) Estephania Candelo, Léa Cochard, Gabriela Caicedo-Herrera, Ana M. Granados, Juan F. Gomez, Lorena Díaz-Ordoñez, Diana Ramirez-Montaño, and Harry Pachajoa. Syndromic progressive neurodegenerative disease of infancy caused by novel variants in hibch: report of two cases in colombia. Intractable &amp; Rare Diseases Research, 8(3):187–193, August 2019. URL: http://dx.doi.org/10.5582/irdr.2019.01014, doi:10.5582/irdr.2019.01014. This article has 7 citations.](https://doi.org/10.5582/irdr.2019.01014)

[8. (Loupatty2007Mutations) Ference J. Loupatty, Peter T. Clayton, Jos P.N. Ruiter, Rob Ofman, Lodewijk IJlst, Garry K. Brown, David R. Thorburn, Robert A. Harris, Marinus Duran, Carlos DeSousa, Steve Krywawych, Simon J.R. Heales, and Ronald J.A. Wanders. Mutations in the gene encoding 3-hydroxyisobutyryl-coa hydrolase results in progressive infantile neurodegeneration. The American Journal of Human Genetics, 80(1):195–199, January 2007. URL: http://dx.doi.org/10.1086/510725, doi:10.1086/510725. This article has 74 citations.](https://doi.org/10.1086/510725)